BioCentury
ARTICLE | Company News

Oxford BioMedica and Novartis expand supply agreement for lentiviral vectors for tisagenlecleucel-T

July 28, 2017 7:51 PM UTC

Oxford BioMedica plc (LSE:OXB) will supply GMP grade lentiviral vectors to Novartis AG (NYSE:NVS; SIX:NOVN) which the pharma will use for the commercial and clinical supply of chimeric antigen receptor (CAR) T cell therapy tisagenlecleucel-T (CTL019) and other undisclosed CAR T products under an expanded 2014 deal. The three-year deal can be extended to five years.

Under the expansion, Oxford is eligible to receive more that $100 million, which includes a $10 million upfront payment and milestones, over the next three years. Oxford is also eligible for royalties. ...

BCIQ Company Profiles

Novartis AG

Oxford BioMedica plc